Search results
Results From The WOW.Com Content Network
Cipla was founded in Mumbai in 1935 by Khwaja Abdul Hamied as the Chemical, Industrial & Pharmaceutical Laboratories. [ 6 ] [ 7 ] In July 1984, the name of the company was changed to 'Cipla'. [ 7 ]
Orchid Pharma Limited is an Indian pharmaceutical company based in Chennai, founded on 1 July 1992. As of 2024, it was among the top fortune 500 Indian companies by market capitalization. Orchid Pharma is the only pharma company in India to have discovered a New Drug (NCE) Enmetazobactam which is now approved in United States, Europe and India.
The foundation for this group was laid by Dewan Bahadur A.M.Murugappa Chettiar who established a money-lending and banking business in 1900. [8]The business was first up in Moulmein, Burma (now Myanmar) [9] and then spread to British Malaya, Ceylon, Dutch East Indies and French Indo-China.
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. [1] India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports.
Alagappa College of Technology is an educational institution located in Chennai, Tamil Nadu, India that offers higher education in engineering, technology and allied sciences. The college was established in 1944 and was integrated with Anna University in 1978 from University of Madras as a constituent part of Anna University within its Guindy ...
SRF Limited is an Indian multi-business chemicals conglomerate engaged in the manufacturing of industrial and specialty intermediates.The company’s business portfolio covers fluorochemicals, specialty chemicals, packaging films, technical textiles, coated and laminated fabrics. [2]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
On 7 April 2014, India-based Sun Pharmaceutical and Japan-based Daiichi Sankyo jointly announced the sale of the entire 63.4% share of Ranbaxy from Daiichi Sankyo to Sun Pharmaceutical in a $4 billion all-share deal. Under these agreements, shareholders of Ranbaxy were to receive a 0.8 share of Sun Pharmaceutical for each share of Ranbaxy. [3]